# Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

> **NCT06942234** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 180 (estimated)

## Conditions studied

- Inoperable Locally Advanced HER2-Negative Breast Cancer
- Metastatic HER2-Negative Breast Cancer

## Interventions

- **DRUG:** JSKN016
- **DRUG:** Capecitabine
- **DRUG:** Paclitaxel (albumin bound)
- **DRUG:** Eribulin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06942234
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06942234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06942234, "Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06942234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*